What top creators are saying about UnitedHealth Group Incorporated(UNH)— Page 2

Not recommended for bottom-fishing as its long-term uptrend is considered broken, unlike pharma and biotech stocks in the same sector.

Identified as one of the worst performers from 2025 that has a good chance to rebound in 2026, making it a potential turnaround play.

Showed significant declines at -34.74%, suggesting potential areas for caution or short opportunities.

Proactively managing the risk of drug pricing regulation by publicly marketing its efforts to save consumers money, which builds goodwill and could aid customer retention.

Part of the worst-performing healthcare subsector (medical insurance) due to higher-than-expected cost increases; the stock was down 33%.

The company is proactively managing political and social risks by working to lower prescription drug costs, which could build a competitive advantage, customer loyalty, and a more sustainable business model.

Faces significant headwinds from expiring ACA subsidies, which could shrink its customer base. The company is experiencing extreme negative public sentiment and high reputational risk due to rising healthcare costs.

Mentioned as a potential 'buy the dip' opportunity after a significant sell-off, representing an attractive entry point for investors bullish on the U.S. healthcare industry.

Gained 2-3% on news of a potential extension of ACA subsidies, which is viewed as a positive catalyst for the managed care sector.

Specifically named in a very negative light, with the podcast suggesting a 'corrupt flow of money' between the government and the insurance giant, highlighting significant reputational risk.

Cited as an example of a defensive healthcare stock that investors may rotate into during periods of tech weakness.

Mentioned as a healthcare/defensive name that is seeing inflows as part of a healthy market rotation away from tech stocks.

Sentiment is very bullish as the stock is one of the top three being bought by institutional investors according to 13F filings and is showing very strong price momentum.

Stock was down 2.6% due to uncertainty surrounding the extension of ACA subsidies, which was delayed in the government shutdown deal.

An agreement to extend ACA subsidies, which is considered likely, would be a bullish catalyst as it would help maintain its customer base.

Mentioned as a notable strong performer indicating positive market sentiment.

Reported strong earnings and provided better-than-expected guidance, signaling to the market that its focus on profitability and margin recovery is on the right track.

The company's 2025 earnings estimates have been 'slashed nearly in half' due to rising healthcare costs and Medicare reimbursement issues, indicating significant problems.

Faces significant reputational risk due to widespread customer dissatisfaction and negative sentiment over denying claims, creating an opening for competitors or future regulation.

The technical setup is attractive for a trade 'right now,' as it's breaking out above $362.57 and looks poised for a quick move to the $377-$380 area to fill a price gap.

The stock saw gains as the broader healthcare sector reacted positively to political discussions around extending ACA subsidies.

Faces significant event risk and stock price volatility due to political uncertainty surrounding the Affordable Care Act (ACA) tax credits. An expiration could lead to a mass exodus of customers from the marketplace, hurting revenue.

Faces significant regulatory and business model risk due to widespread negative sentiment towards its Pharmacy Benefit Manager (PBM) division, as highlighted by criticism from pharmaceutical executives.

Highlighted as a successful example of an 'anti-momentum' investment; a high-quality company that was trading at historically low relative valuations but has since recovered significantly.

Faces deep, structural problems from the V28 risk model revision, which disproportionately harms its Optum Health division. Analyst notes an 'underperform' rating, 'appalling' lack of disclosure, and accounting concerns, with a bull case scenario of $257 representing significant downside.

The company is flagged for a 'real potential scandal' and 'incredible depth of its problems,' signaling significant potential negative news and risk for investors.

The host is bullish on a long-term recovery, viewing the company's current problems as temporary. It's seen as an opportunity to buy a market leader at a discounted valuation while it works through a known headwind.

As a large, vertically integrated insurer with a PBM, the company's business model is highlighted as being at risk from both new competitors with transparent pricing and potential government regulation.

A dominant force in the U.S. healthcare system with a powerful moat built on immense scale, though investors should remain aware of persistent risks from government regulation.

Stock is down significantly (in the 40% to 53% range) due to 'absolute carnage' in the managed care sector from rising healthcare costs.

Considered an undervalued defensive healthcare stock whose poor performance is very unusual, especially after a major investment from Warren Buffett and its price falling below $300.

The company is portrayed in an extremely negative light, described as a 'con game' that uses AI to systematically deny care for profit, leading to significant reputational risk and potential for regulatory scrutiny.

Mentioned as an example of a value-oriented stock that was performing well, benefiting from a healthy market rotation out of big tech.

Legendary value investors Warren Buffett and Michael Burry both took bullish positions, signaling they believe the stock is significantly undervalued. The investment is a deep value play based on a turnaround story, betting that temporary earnings problems from underpricing insurance will correct over time.

Significant insider buying ($30M+) and a new position by Berkshire Hathaway after a price drop suggest high confidence and a potential buying opportunity, as the current price is below the insider purchase price.

Described as a 'textbook case' of a company in trouble, having missed revenue and earnings, being under federal investigation, and having 'gutted its guidance' for 2024.

The revelation that it was the #1 most bought stock by 'super investors' in Q2 provided a powerful catalyst, suggesting the stock has likely bottomed out. However, lingering regulatory and legal risks could lead to sideways trading.

A 'sum-of-the-parts' analysis concludes the company is fairly valued. It is viewed as a mature value company, not a growth opportunity, with the advice to 'stay away'.

Showing strong momentum, with major investors like Buffet and Tepper accumulating shares, suggesting a long-term bullish outlook and potential for further upside from institutional buying.

A significant number of 'super investors' like Warren Buffett and David Tepper bought UNH in Q2, suggesting they see deep value despite risks like a DOJ investigation. This is viewed as a 'follow the smart money' play.

A new institutional favorite, with major players accumulating shares and a long-term bullish outlook, suggesting continued money flow into the stock.

Michael Burry, a prominent investor, has reportedly added $115 million of UnitedHealth Group (UNH) to his portfolio, signaling a bullish outlook.

Warren Buffett and David Tepper have recently increased their stakes, signaling strong institutional confidence.

Warren Buffett's Berkshire Hathaway purchased 5 million shares, which is considered a bullish indicator and a signal of confidence in the company.

Considered a potential bullish 'comeback trade' and a buying opportunity for a high-quality company while market sentiment is overly negative.

Noted as the #1 stock being bought by 'super investors' in the most recent quarter. Viewed as a potential defensive/value stock to own during a tech correction.

A Congressman with a role on the subcommittee investigating Medicaid purchased the stock, suggesting a potentially bullish outlook based on his informed position. This is seen as a speculative bet on a recovery.

Mentioned as one of the top buys by 'super investors' in Q2 2024 based on early 13F filings, suggesting positive institutional interest.

Considered 'cheap for a reason' due to a DOJ investigation and the risk of 'multiple compression.' The host sees it as a less attractive opportunity than tech stocks, despite a potential path to $400 over a five-year horizon.

Very bearish call, stating there is 'something flawed with their business model' and that the company has been 'playing games with their earnings.' The stock's 'stunning drop' is seen as confirmation of deep-seated problems.